LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 174

Search options

  1. Article ; Online: The Concept of Transient Ischemic Attack-Reply.

    Easton, J Donald / Johnston, S Claiborne

    JAMA

    2022  Volume 327, Issue 24, Page(s) 2457

    MeSH term(s) Humans ; Ischemic Attack, Transient
    Language English
    Publishing date 2022-06-28
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2022.7630
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Time to Retire the Concept of Transient Ischemic Attack.

    Easton, J Donald / Johnston, S Claiborne

    JAMA

    2022  Volume 327, Issue 9, Page(s) 813–814

    MeSH term(s) Humans ; Ischemic Attack, Transient ; Terminology as Topic
    Language English
    Publishing date 2022-02-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2022.0300
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Baseline Stroke Risk and Efficacy of Dual-Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial.

    Daghlas, Iyas / Johnston, S Claiborne / Easton, J Donald / Kim, Anthony S

    Stroke

    2024  Volume 55, Issue 2, Page(s) 385–391

    Abstract: Background: High-risk transient ischemic attacks and minor ischemic strokes are followed by a variable risk of ischemic stroke. We aimed to determine how baseline stroke risk modified the efficacy of clopidogrel-aspirin (referred to here as dual- ... ...

    Abstract Background: High-risk transient ischemic attacks and minor ischemic strokes are followed by a variable risk of ischemic stroke. We aimed to determine how baseline stroke risk modified the efficacy of clopidogrel-aspirin (referred to here as dual-antiplatelet therapy [DAPT]) for transient ischemic attack and minor ischemic stroke.
    Methods: We performed an unplanned secondary analysis of the POINT trial (Platelet-Oriented Inhibition in New Transient Ischemic Attack and Minor Ischemic Stroke). We first evaluated the associations of the CHA
    Results: A total of 4841 trial participants were included in this analysis, with 2400 participants assigned to treatment with short-term DAPT and 2430 participants to treatment with aspirin and placebo. The dichotomized SPI-II score, but not the CHA
    Conclusions: Stratification by baseline stroke risk identifies a patient subgroup that derives greater absolute benefit from treatment with DAPT.
    Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00991029.
    MeSH term(s) Humans ; Aspirin/adverse effects ; Drug Therapy, Combination ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Hemorrhage/complications ; Ischemic Attack, Transient/drug therapy ; Ischemic Attack, Transient/epidemiology ; Ischemic Attack, Transient/complications ; Ischemic Stroke/drug therapy ; Platelet Aggregation Inhibitors/adverse effects ; Risk Factors ; Stroke/epidemiology ; Stroke/prevention & control ; Stroke/complications ; Treatment Outcome ; Clinical Trials as Topic
    Chemical Substances Aspirin (R16CO5Y76E) ; Platelet Aggregation Inhibitors
    Language English
    Publishing date 2024-01-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80381-9
    ISSN 1524-4628 ; 0039-2499 ; 0749-7954
    ISSN (online) 1524-4628
    ISSN 0039-2499 ; 0749-7954
    DOI 10.1161/STROKEAHA.123.044927
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Henry J.M. Barnett, MD, FRCP (C).

    Easton, J Donald

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

    2016  Volume 25, Issue 12, Page(s) 2791

    MeSH term(s) Biomedical Research/history ; History, 20th Century ; History, 21st Century ; Humans ; Neurology/history ; Stroke/history ; Stroke/prevention & control
    Language English
    Publishing date 2016-12
    Publishing country United States
    Document type Biography ; Historical Article ; Journal Article
    ZDB-ID 1131675-5
    ISSN 1532-8511 ; 1052-3057
    ISSN (online) 1532-8511
    ISSN 1052-3057
    DOI 10.1016/j.jstrokecerebrovasdis.2016.10.036
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: New opportunities to optimize antithrombotic therapy for secondary stroke prevention.

    Kim, Anthony S / Easton, J Donald

    International journal of stroke : official journal of the International Stroke Society

    2019  Volume 14, Issue 3, Page(s) 220–222

    Abstract: Stroke symptoms can be unsettling, even when symptoms resolve, but focusing on stroke prevention can be empowering provided that effective interventions for appropriate patient populations are available. Current options include interventions for ... ...

    Abstract Stroke symptoms can be unsettling, even when symptoms resolve, but focusing on stroke prevention can be empowering provided that effective interventions for appropriate patient populations are available. Current options include interventions for symptomatic carotid artery stenosis, anticoagulation for atrial fibrillation, high-dose statins, new oral anticoagulants, new developments in atrial fibrillation detection, and new therapeutics are in development. For antiplatelet therapy, aspirin monotherapy is effective but dual antiplatelet therapy with the combination of aspirin and clopidogrel increases hemorrhage risks over the long term that outweigh potential benefits. In the short term though, both the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials have shown a benefit of short-term dual-antiplatelet therapy, though the increased major hemorrhage risk seen in POINT could justify applying dual-antiplatelet therapy to just the first 21 days. Furthermore, since clopidogrel is a prodrug that must be metabolized to have antiplatelet activity, it is not surprising that the treatment effect in CHANCE was limited to patients who were not carriers of loss-of-function alleles for clopidogrel metabolism. Ticagrelor, an antiplatelet agent which failed to meet its primary endpoint as monotherapy compared to aspirin in the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial, is currently being tested as combination therapy with aspirin compared to aspirin alone in Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES). These developments along with improvements to the infrastructure to perform rapid evaluations and to apply intensive secondary stroke prevention interventions hold continued promise for the future.
    MeSH term(s) Aspirin/therapeutic use ; Clopidogrel/therapeutic use ; Drug Therapy, Combination ; Fibrinolytic Agents/therapeutic use ; Humans ; Ischemic Attack, Transient/drug therapy ; Platelet Aggregation Inhibitors/therapeutic use ; Secondary Prevention ; Stroke/drug therapy ; Ticagrelor/therapeutic use ; Ticlopidine/therapeutic use ; Treatment Outcome
    Chemical Substances Fibrinolytic Agents ; Platelet Aggregation Inhibitors ; Clopidogrel (A74586SNO7) ; Ticagrelor (GLH0314RVC) ; Ticlopidine (OM90ZUW7M1) ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2019-02-06
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2303728-3
    ISSN 1747-4949 ; 1747-4930
    ISSN (online) 1747-4949
    ISSN 1747-4930
    DOI 10.1177/1747493019828548
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: History of carotid endarterectomy then and now: personal perspective.

    Easton, J Donald

    Stroke

    2014  Volume 45, Issue 6, Page(s) e101–3

    MeSH term(s) Carotid Arteries/surgery ; Endarterectomy, Carotid/history ; Endarterectomy, Carotid/methods ; History, 20th Century ; History, 21st Century ; Humans
    Language English
    Publishing date 2014-06
    Publishing country United States
    Document type Historical Article ; Journal Article ; Review
    ZDB-ID 80381-9
    ISSN 1524-4628 ; 0039-2499 ; 0749-7954
    ISSN (online) 1524-4628
    ISSN 0039-2499 ; 0749-7954
    DOI 10.1161/STROKEAHA.113.003501
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Review and update of the concept of embolic stroke of undetermined source.

    Diener, Hans-Christoph / Easton, J Donald / Hart, Robert G / Kasner, Scott / Kamel, Hooman / Ntaios, George

    Nature reviews. Neurology

    2022  Volume 18, Issue 8, Page(s) 455–465

    Abstract: Ischaemic strokes have traditionally been classified according to the TOAST criteria, in which strokes with unclear aetiology are classified as cryptogenic strokes. However, the definition of cryptogenic stroke did not meet the operational criteria ... ...

    Abstract Ischaemic strokes have traditionally been classified according to the TOAST criteria, in which strokes with unclear aetiology are classified as cryptogenic strokes. However, the definition of cryptogenic stroke did not meet the operational criteria necessary to define patient populations for randomized treatment trials. To address this problem, the concept of embolic stroke of undetermined source (ESUS) was developed and published in 2014. A hypothesis that underpinned this concept was that most strokes in patients with ESUS are caused by embolic events, perhaps many cardioembolic, and that anticoagulation would prevent secondary ischaemic events. On this basis, two large randomized trials were conducted to compare the non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran and rivaroxaban with aspirin. Neither NOAC was superior to aspirin in these trials, although subgroups of patients with ESUS seemed to benefit specifically from anticoagulation or antiplatelet therapy. The neutral results of the trials of anticoagulation and insights into ESUS from research conducted since the concept was introduced warrant reassessment of the ESUS construct as a research concept and a treatment target. In this Review, we discuss the evidence produced since the concept of ESUS was introduced, and propose updates to the criteria and diagnostic algorithm in light of the latest knowledge.
    MeSH term(s) Administration, Oral ; Anticoagulants/therapeutic use ; Aspirin ; Embolic Stroke ; Humans ; Intracranial Embolism/complications ; Ischemic Stroke ; Platelet Aggregation Inhibitors/therapeutic use ; Stroke/diagnosis ; Stroke/drug therapy ; Stroke/etiology
    Chemical Substances Anticoagulants ; Platelet Aggregation Inhibitors ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2022-05-10
    Publishing country England
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2491514-2
    ISSN 1759-4766 ; 1759-4758
    ISSN (online) 1759-4766
    ISSN 1759-4758
    DOI 10.1038/s41582-022-00663-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).

    Easton, J Donald

    Current atherosclerosis reports

    2011  Volume 13, Issue 4, Page(s) 314–320

    Abstract: The new definition and risk stratification for transient ischemic attack (TIA) have clear implications for the urgency of evaluation and treatment. The optimal antithrombotic treatment for TIA is being intensively studied. New guidelines for prevention ... ...

    Abstract The new definition and risk stratification for transient ischemic attack (TIA) have clear implications for the urgency of evaluation and treatment. The optimal antithrombotic treatment for TIA is being intensively studied. New guidelines for prevention of non-cardioembolic stroke in patients with stroke or TIA recommend the use of antiplatelet agents rather than oral anticoagulation. New antiplatelet drugs are being used in cardiovascular patients, and their role in cerebrovascular patients is being studied. The impact of genetic CYP2C19 polymorphisms is becoming clarified in cardiovascular patients and it is likely these polymorphisms will affect the management of cerebrovascular patients. The results of trials of clopidogrel plus aspirin in patients with lacunar strokes and acute TIAs are forthcoming. The results of CLOSURE I, a study of a patent foramen ovale device closure trial for cryptogenic stroke or TIA, showed no differences in stroke or TIA at 2 years.
    MeSH term(s) Adenosine/analogs & derivatives ; Adenosine/therapeutic use ; Aryl Hydrocarbon Hydroxylases/genetics ; Brain Ischemia/drug therapy ; Cilostazol ; Clinical Trials as Topic ; Clopidogrel ; Cytochrome P-450 CYP2C19 ; Cytochrome P-450 Enzyme System/genetics ; Fibrinolytic Agents/therapeutic use ; Foramen Ovale, Patent/therapy ; Genotype ; Humans ; Ischemic Attack, Transient/drug therapy ; Piperazines/therapeutic use ; Platelet Aggregation Inhibitors/therapeutic use ; Polymorphism, Genetic ; Prasugrel Hydrochloride ; Risk Assessment ; Risk Factors ; Stroke/drug therapy ; Tetrazoles/therapeutic use ; Thiophenes/therapeutic use ; Ticagrelor ; Ticlopidine/analogs & derivatives ; Ticlopidine/therapeutic use
    Chemical Substances Fibrinolytic Agents ; Piperazines ; Platelet Aggregation Inhibitors ; Tetrazoles ; Thiophenes ; Cytochrome P-450 Enzyme System (9035-51-2) ; Clopidogrel (A74586SNO7) ; Aryl Hydrocarbon Hydroxylases (EC 1.14.14.1) ; CYP2C19 protein, human (EC 1.14.14.1) ; Cytochrome P-450 CYP2C19 (EC 1.14.14.1) ; Prasugrel Hydrochloride (G89JQ59I13) ; Ticagrelor (GLH0314RVC) ; Adenosine (K72T3FS567) ; Cilostazol (N7Z035406B) ; Ticlopidine (OM90ZUW7M1)
    Language English
    Publishing date 2011-05-17
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057369-8
    ISSN 1534-6242 ; 1523-3804
    ISSN (online) 1534-6242
    ISSN 1523-3804
    DOI 10.1007/s11883-011-0185-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Risk of Stroke after Transient Ischemic Attack or Minor Stroke.

    Kim, Anthony S / Easton, J Donald / Johnston, S Claiborne

    The New England journal of medicine

    2016  Volume 375, Issue 4, Page(s) 386–387

    MeSH term(s) Female ; Humans ; Ischemic Attack, Transient/complications ; Male ; Stroke/etiology
    Language English
    Publishing date 2016-07-28
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc1606657#SA1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3): Rationale and design of a multicenter randomized placebo-controlled trial.

    Wang, Yongjun / Li, Jiejie / Johnston, S Claiborne / Hankey, Graeme J / Easton, J Donald / Meng, Xia / Shi, Fu-Dong / Wang, Yilong / Zhao, Xingquan / Li, Zixiao / Liu, Liping / Gu, Hongqiu / Jiang, Yong / Wang, Anxin / Pan, Yuesong / Jing, Jing / Niu, Siying / Li, Hao

    International journal of stroke : official journal of the International Stroke Society

    2023  Volume 18, Issue 7, Page(s) 873–878

    Abstract: Background: Anti-inflammatory therapy using colchicine has reduced recurrent vascular events in patients with coronary heart disease.: Design: Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack ( ...

    Abstract Background: Anti-inflammatory therapy using colchicine has reduced recurrent vascular events in patients with coronary heart disease.
    Design: Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3) is a randomized, double-blind, placebo-controlled multicenter trial, in which 8,238 patients with acute minor-to-moderate ischemic stroke (NIHSS ⩽ 5) or high-risk transient ischemic attack (TIA) (ABCD
    Trial registry name: Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3);
    MeSH term(s) Humans ; Ischemic Attack, Transient/drug therapy ; Stroke/drug therapy ; Stroke/chemically induced ; Platelet Aggregation Inhibitors/therapeutic use ; Aspirin/therapeutic use ; Ischemic Stroke/drug therapy ; Clopidogrel/therapeutic use ; Colchicine/therapeutic use
    Chemical Substances Platelet Aggregation Inhibitors ; Aspirin (R16CO5Y76E) ; Clopidogrel (A74586SNO7) ; Colchicine (SML2Y3J35T)
    Language English
    Publishing date 2023-05-11
    Publishing country United States
    Document type Randomized Controlled Trial ; Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2303728-3
    ISSN 1747-4949 ; 1747-4930
    ISSN (online) 1747-4949
    ISSN 1747-4930
    DOI 10.1177/17474930231172312
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top